INTRODUCTION
============

The neurotrophin nerve growth factor (NGF) is involved in several critical processes in the developing and mature mammalian nervous system, including target innervation, cell differentiation and neuronal survival ([@B36]; [@B40]; [@B56]; [@B35]). In the adult brain, NGF plays a key role in the maintenance and function of the basal forebrain cholinergic system ([@B35]). Levels of NGF are highest in areas receiving the greatest number of basal forebrain cholinergic projections, namely the hippocampus and cortex ([@B34]; [@B55]), and receptors for NGF in the cortex are largely confined to basal forebrain corticopetal projections ([@B32]; [@B56]; [@B52]). Nerve growth factor signaling maintains cholinergic corticopetal projections during adulthood ([@B7]; [@B15]) and can prevent degeneration of these neurons following transection of their axons ([@B23]; [@B58]; [@B33]). Furthermore, NGF enhances release of acetylcholine from basal forebrain cultures ([@B1]) and can modulate cholinergic function through phenotypic control of the cholinergic gene locus ([@B53]; [@B27]).

The basal forebrain cholinergic system influences learning and experience-dependent plasticity in the cortex ([@B2]; [@B31]; [@B9], [@B8]), and NGF signaling has been hypothesized to support, and possibly enhance, basal forebrain-mediated learning and plasticity. For example, blockade of NGF signaling via repeated injections of NGF antibodies in the insular cortex reduces local cholinergic innervation and disrupts acquisition of two processes that depend on the integrity of cholinergic inputs, conditioned taste aversion and inhibitory avoidance learning ([@B20]). A recent study by [@B10] demonstrated that both spatial learning and hippocampal long-term potentiation (LTP) are enhanced following infusions of NGF into the septal nucleus, the primary source of cholinergic innervation to the hippocampus.

Focal application of NGF can also induce rapid expansion of the local whisker representation in the barrel cortex of rats. This process is dependent on cholinergic projections from the basal forebrain ([@B49], [@B50]), suggesting that cortical NGF signaling can stimulate rapid cholinergic-dependent functional reorganization. Thus, in addition to its long-term trophic effects on basal forebrain cholinergic cells, NGF may also participate in short-term circuit remodeling. This "dual-action" hypothesis is supported by the existence of constitutive and activity-dependent release mechanisms of NGF ([@B4]; [@B39]), potentially underlying the long-term trophic and short-term modulatory effects of NGF, respectively. Moreover, both retrograde (long-term) and local (short-term) signaling pathways have been observed for NGF ([@B28]).

Cells expressing NGF have been detected in the cortex, cerebellum, hippocampus, thalamus, striatum, basal forebrain and brainstem ([@B19]; [@B41]; [@B29]; [@B12]; [@B22]; [@B44]; [@B62]). Although NGF mRNA has been reportedly observed in astrocytes and other glia, the vast majority of cortical NGF is produced by neurons ([@B56]). The specific types of neurons that produce NGF in the cortex are not known, however, and cholinergic corticopetal projections have been shown to innervate both excitatory and inhibitory neurons in the cortex ([@B61]). In extracortical regions such as the hippocampus, striatum and basal forebrain, NGF production is predominantly localized to GABAergic inhibitory neurons ([@B38], [@B37]; [@B45]; [@B3]). Identification of NGF-producing cells in the cortex is important for identifying potential mechanisms underlying modulation of cholinergic cortical inputs, and mechanisms of cortical plasticity. In the current study, we identify a subset of cortical GABAergic cells as the primary source of NGF production in the adult cortex, with relatively rare production by glutamatergic neurons.

MATERIALS AND METHODS {#s1}
=====================

All subjects were treated in accordance with institutional guidelines for animal care. Due to low endogenous levels of cortical NGF expression that prohibited identification of specific cell--type sources of NGF in previous studies, we performed local colchicine infusions to inhibit microtubule polymerization, thereby blocking NGF transport away from the cell body and resulting in accumulation of detectable NGF antigen in the soma of producing cells ([@B54]; [@B25]; [@B21]; [@B12]). Previous reports have shown that colchicine treatment increases detection of NGF using immunohistochemical techniques ([@B12]). Furthermore, colchicine levels similar to that used in the current study do not to induce gross abnormalities in neuronal distribution of the neurotrophin family member BDNF ([@B11]).

TISSUE PREPARATION
------------------

Eight adult Fischer 344 rats (4 male, 4 female; Harlan Sprague Dawley) were anesthetized with 2 ml/kg of a 25 mg/ml ketamine, 1.3 mg/ml xylazine, and 0.25 mg/ml acepromazine cocktail, and injected with 5.0 μl colchicine (10 μg/μl in aCSF) at the cortical locations listed below at a rate of 0.5 μl/min using a 10 μl Hamilton syringe. Following infusion, the needle remained in place for four minutes to allow adequate diffusion to the surrounding tissue. Four animals received bilateral injections in the primary motor cortex (M1) at +1.2 mm anterior (A/P) and ±2.5 mm lateral (M/L) to bregma. Half the solution was injected at 1.6 mm below the surface of the brain (D/V), and the rest at 1.0 mm. The remaining four animals all received unilateral injections in the prefrontal cortex (A/P: +3.0, M/L: +0.5, D/V: -2.3 and -1.8), temporal cortex (A/P: -6.5, M/L: +5.0, D/V: -7.5 and -7.0), and parietal cortex (A/P: -3.0, M/L: +5.0, D/V: -1.8 and -1.3). After 48 h, animals were deeply anesthetized and transcardially perfused with 250 ml cold phosphate buffered saline (pH 7.4), followed by 250 ml of cold 2% paraformaldehyde + 0.2% parabenzoquinone in 0.1 M phosphate buffer. Brains were extracted, postfixed for 2 h in the same fixative, and cryoprotected in 0.1 M phosphate buffer containing 30% sucrose for at least 72 h at 4°C. Coronal sections (40 μm) were cut on a freezing sliding microtome and stored in cryoprotectant (TCS) at 4°C until further processed for immunohistochemistry.

DOUBLE-LABEL FLUORESCENCE IMMUNOHISTOCHEMISTRY
----------------------------------------------

Sequential double-label immunohistochemistry was used to visualize neurons expressing NGF and either GABAergic or glutamatergic cell markers. Free-floating sections were washed in Tris Buffered Saline (TBS), permeabilized with 0.25% Triton X-100, and nonspecific labeling was then blocked with 5% donkey serum. Sections were incubated for 72 h at 4°C in rabbit anti-NGF antibody ([@B12]) diluted 1:1000 in TBS, 0.25% Triton X-100, and 5% donkey serum. Following primary antibody incubation, sections were incubated in donkey anti-rabbit biotin-conjugated IgG (1:200; Vector Laboratories, Burlingame, CA, USA). Tyramide signal amplification (TSA; PerkinElmer, Waltham, MA, USA) was applied to amplify the NGF signal, after which sections were washed in TBS and incubated in Alexa Fluor 488 or 594-conjugated streptavidin (Invitrogen, Carlsbad, CA, USA) diluted 1:200 for 3 h at 4°C. After a brief wash, sections were incubated in both mouse anti-glutamate decarboxylase (GAD) 65 (GAD-6, AntibodyRegistry:AB_528264,1:2000; Developmental Studies Hybridoma Bank, Iowa City, IA, USA) and mouse anti-GAD67 (AnitbodyRegistry: AB_2278725, 1:1500; Millipore, Temecula, CA, USA), or in mouse anti-parvalbumin (AntibodyRegistry: AB_2174013, 1:30000; Millipore, Temecula, CA, USA), mouse anti-calbindin-D-28K (AntibodyRegistry: AB_476894, 1:1500; Sigma-Aldrich, St. Louis, MO, USA), or mouse anti-Ca^2+^/calmodulin-dependent protein kinase IIα (CaMKIIα, AntibodyRegistry: AB_2067919, 1:1500; Millipore) for 72 h at 4°C. Finally, sections were washed, incubated in Alexa Fluor 594 or 488-conjugated donkey anti-mouse (Invitrogen) for 3 h at room temperature, washed again, mounted on glass slides, and coverslipped in Fluoromount-G (Southern Biotech, Birminghan, AL, USA). In order to maximize identification of GABAergic cells, GAD65 and GAD67 antibodies were co-incubated. A subset of sections was coverslipped in ProLong Gold with DAPI (Invitrogen) for visualization of cell nuclei.

ANTIBODY CHARACTERIZATION
-------------------------

The NGF antibody used in this study is an affinity-purified polyclonal raised in rabbit against purified mouse NGF ([@B12]). The antibody recognizes purified mouse and recombinant human NGF but does not cross react with recombinant BDNF or NT-3 ([@B13]). Furthermore, the immunoreactive pattern of NGF expression in the rat brain closely matches that obtained from in-situ analysis in the rat brain ([@B14]).

The monoclonal antibody GAD-65 (Developmental Studies Hybridoma Bank, Gad-6) was produced by immunizing mice with GAD protein immunoaffinity-purified from rat brain. Western blot analysis of rat brain homogenates revealed the antibody selectively recognizes GAD-65 but not GAD-67 ([@B6]). Additional studies have shown that the GAD-6 antibody recognizes an epitope located between amino acids 475--571 of the C-terminus of GAD-65 ([@B5]).

The GAD-67 mouse monoclonal (Millipore, MAB 5406, lot: 25010139) was raised against amino acid residues 4-101 of human GAD-67, and recognizes a single 67-kDa band on Western blot analysis of rat brain (manufacturer's technical information). Preincubation of the antibody with a GST-GAD-67 fusion protein resulted in no immunopositive signal in the brain ([@B30]).

The mouse monoclonal anti-CaMKIIα (Millipore, MAB 8699, lot: LV1366080) specifically recognizes the alpha subunit of calcium/calmodulin-dependent protein kinase II. Western blot analysis demonstrates that the antibody identifies a single band of 50 kDa and recognizes both phosphorylated and unphosphorylated forms ([@B17]).

Monoclonal anti-calbindin-D-28k (Sigma--Aldrich, C9848, lot: 088k4799) is derived from BALB/c mice immunized with purified bovine kidney calbindin-D-28k. Immunoblotting showed the antibody recognizes a 28-kDa band, and does not to react with similar molecules, such as calbindin-D-9K, calretinin, myosin light chain, and parvalbumin (manufacturer's technical information). Preabsorption with a calbindin-D-27 kDa protein purified from chick and rat brains was shown to eliminate calbindin immunostaining in the brain ([@B46]).

Anti-parvalbumin (Millipore, MAB 1572, lot: LV1378387) was collected from mice immunized against parvalbumin purified from frog muscle. The monoclonal antibody is directed against an epitope at the first Ca^2+^-binding site and immunoblot analysis demonstrates it recognizes a brain protein of 12 kDa (manufacturer's technical information).

CONFOCAL ANALYSIS
-----------------

Images were captured using an Olympus AX70 with Magnafire software (version 2.0; Karl Storz Imaging, Goleta, CA, USA). Because NGF labeling was reduced substantially approximately 2 mm anterior/posterior to colchicine injection sites, presumably due to a lack of colchicine diffusion and the resulting absence of somatic NGF accumulation, only sections within 1.5 mm of each colchicine injection site were analyzed. Every 10^th^ section (400 μm) was examined within a cortical region. Cells were manually counted, and at least three sections were analyzed in each cortical region and antibody combination per subject. Only three animals were evaluated in the temporal region due to undetectable NGF labeling in the fourth. Single and double-labeled cells were quantified using both single and double-channel images. Several criteria were used to identify labeled cells, including size, morphology, signal vs. background, and coincident DAPI labeling when assessing DAPI-stained tissue. In a subset of sections, 5 μm z-stacks were collected using an Olympus Fluoview FV1000 to ensure neuronal localization of the labeled object. Due to our interest in the proportion, and not the absolute number, of double-labeled cells, stereological methods were not used.

The percentage of double-labeled cells per immunoreactive (IR) cell group was determined for each image field. Mean ± standard error was calculated for each cortical region examined. One-way analysis of variance (ANOVA) was used to evaluate differences among cortical regions. Fisher's HSD was used for post-hoc analysis. All statistical analyses were carried out with SPSS 15.0 for Windows.

ANTIBODY CONTROLS
-----------------

Controls included omission of primary antibodies, omission of secondary antibodies, and replacement of primary antibody with nonspecific antibody (rabbit IgG). All manipulations had the expected effects and supported the assertion that labeled cells represent true antigen labeling by their corresponding antibodies.

RESULTS
=======

NGF IMMUNOLABELING
------------------

Distinct NGF labeling was visible within a radius of 1.5 mm from colchicine cortical injection sites. Within these areas, NGF labeling was predominantly confined to cell somata (**Figure [1](#F1){ref-type="fig"}**). Rarely, one or more cellular processes could also be distinguished. Outside of this 1.5 mm radius, NGF labeling was virtually undetectable in the cortex. As cortical expression of the NGF receptors TrkA and p75 are confined to cholinergic corticopetal fibers, the observed labeling of NGF is unlikely to reflect endocytosed NGF, but instead is indicative of NGF-producing cells ([@B26]; [@B52]; [@B57]). As reported previously ([@B51]), colchicine treatment intensified GAD labeling in cell bodies as well as neuronal processes. Colchicine had no detectable effect on labeling for parvalbumin, calbindin, or CaMKIIα.

![**Nerve growth factor colocalizes extensively with inhibitory cell markers.** Immunoreactive cells in the **(A)** primary motor cortex and **(B)** prefrontal cortex. Images show that NGF-labeled cells (green) colocalize extensively with GAD 65/67-labeled cells (red). White arrows show an example cell immunoreactive for both NGF and GAD 65/67 in each cortical region. Blue arrows show cells immunoreactive for GAD 65/67 only. **(C)** Magnified image of area inside white box in **(B)**. **(D)** *X*--*Y*--*Z* reconstruction of the double-labeled cell indicated in **(C)**. Green and Blue lines indicate dissection levels in *XZ* and *YZ* planes, respectively. Scale bars = 25 μm.](fncel-08-00220-g001){#F1}

NGF AND GABAergic CO-LOCALIZATION
---------------------------------

Nerve growth factor co-localized extensively with the GABAergic cell markers GAD65 and GAD67, regardless of the cortical area examined (**Figure [1](#F1){ref-type="fig"}**; **Table [1](#T1){ref-type="table"}**). Overall, 91 ± 0.9% of NGF-labeled cortical cells also labeled for GAD65/67. The percentage of NGF-labeled cells co-expressing GAD65/67 showed little difference among the prefrontal (90.0 ± 1.5%), motor (91.7 ± 1.5%), parietal (89.6 ± 3.5%) and temporal (93.4 ± 8.1%) cortices (one-way ANOVA; *p* = 0.78). Conversely, NGF co-localized with only 55 ± 2.3% of all GAD65/67-labeled cells. To determine if NGF production was restricted to a specific subtype of GABAergic neuron, we co-labeled tissue for NGF and either parvalbumin or calbindin (**Figure [2](#F2){ref-type="fig"}**). NGF-labeled cells were observed to colocalize with both markers. However, NGF colocalization with parvalbumin (67.8 ± 3.6%) was over 2× greater than with calbindin (29.1 ± 3.9%). Additionally, NGF-IR cells constituted less than half of all parvalbumin (47.7 ± 4.6%) and calbindin (25.7 ± 4.9%) immunoreactive cells.

![**NGF colabeled with inhibitory neuron subclass markers.** Slices of the motor cortex were labeled for NGF and either parvalbumin or calbindin. **(A)** Cells showed extensive overlap of NGF and parvalbumin labeling (white arrows). **(B)** Conversely, colabeling of NGF and calbindin was less common. Scale Bars = 25 μm.](fncel-08-00220-g002){#F2}

###### 

NGF- and GAD65/67-immunoreactive cells by cortical region.

  Cortical region   NGF I.R. cells   GAD65/67 I.R. cells   Double I.R. cells   \% NGF double I.R.   \% GAD65/67 double I.R.
  ----------------- ---------------- --------------------- ------------------- -------------------- -------------------------
  Prefrontal        180              312                   163                 90.0 ± 1.5           52.2 ± 1.6
  Motor             530              830                   486                 91.7 ± 1.5           58.5 ± 2.2
  Parietal          134              247                   120                 89.6 ± 3.5           48.6 ± 5.1
  Temporal          61               100                   57                  93.4 ± 8.1           57.0 ± 7.3
                                                                                                    
  Total             905              1489                  826                 **91.3**             55.5

Nerve growth factor-expressing neurons were observed throughout all cortical layers. Previous studies have reported uneven distribution of NGF-labeled neurons in the cortical laminae ([@B48]; [@B47]). Quantitative analysis by layer was not performed in the current study, however, as NGF labeling intensity diminished with increasing distance from the colchicine injection site.

NGF AND GLUTAMATERGIC CO-LOCALIZATION
-------------------------------------

Labeling for CaMKIIα was primarily observed within cell somata and proximal processes (**Figure [3](#F3){ref-type="fig"}**). Unlike the extensive co-localization seen with NGF and GABAergic markers, NGF-labeled cells rarely co-localized with CaMKIIα-labeled cells (**Figure [3](#F3){ref-type="fig"}**; **Table [2](#T2){ref-type="table"}**). In total, 4.9 ± 1.1% of NGF-immunoreactive cells were co-labeled with CaMKIIα antibodies. Co-localization differed significantly by cortical region (one-way ANOVA; *p* = 0.03); Fisher's *post hoc* revealed that the prefrontal cortex had a greater proportion of double-labeled NGF cells (7.6 ± 2.1%) compared to the primary motor cortex (2.4 ± 1.0%; *p* = 0.02) and parietal cortex (2.9% ± 1.5; *p* = 0.01).

![**Nerve growth factor colocalizes minimally with the excitatory cell marker CaMKIIα.** Immunoreactive cells in the prefrontal cortex. Cells were rarely colabeled for NGF (green) and CaMKIIα (red), regardless of cortical region examined. Gold arrows show an example of a cell immunoreactive for NGF only. Scale bars = 25 μm.](fncel-08-00220-g003){#F3}

###### 

NGF- and CaMKIIα-immunoreactive cells by cortical region.

  Cortical region   NGF I.R. cells   CaMKIIa I.R. cells   Double I.R. cells   \% NGF double I.R.   \% CaMKIIa double I.R.
  ----------------- ---------------- -------------------- ------------------- -------------------- ------------------------
  Prefrontal        317              649                  24                  7.6 ± 2.1            3.7 ± 1.1
  Motor             125              380                  3                   2.4 ± 1.0            0.8 ± 0.3
  Parietal          240              508                  7                   2.9 ± 1.5            1.4 ± 0.6
  Temporal          182              519                  8                   4.4 ± 1.6            1.5 ± 0.6
                                                                                                   
  Total             864              2056                 42                  4.9                  2.0

Cells immunoreactive for CaMKIIα greatly outnumbered those labeled by NGF antibodies. The overall proportion of CaMKIIα-labeled cells simultaneously expressing NGF signal was 2 ± 0.6%. This percentage differed significantly by region (one-way ANOVA *p* = 0.003), with the prefrontal cortex exhibiting a greater proportion of double-labeled NGF/CaMKIIα cells (3.7 ± 1.1%) than the primary motor cortex (0.8% ± 0.3; *p* = 0.001), the parietal cortex (1.4% ± 0.6; *p* = 0.01), and the temporal cortex (1.5 ± 0.6%; *p* = 0.01).

DISCUSSION
==========

The current study demonstrates that the vast majority (\>90%) of NGF-producing neurons of the cortex are GABAergic, while half of all GABAergic neurons colocalize with NGF. In contrast, markers of excitatory neurons exhibit only rare co-localization with NGF. These results were consistent throughout multiple cortical regions analyzed in this study, indicating that NGF is primarily produced by inhibitory interneurons in the rat neocortex.

Although NGF immunoreactivity rarely coincided with excitatory cell markers (CAMKIIα), a small percentage (\~5%) were positive for CaMKIIα throughout all examined cortical regions. Confocal analysis confirmed that this double labeling originated from the same focal plane, and was not due to discrete signal arising from overlapping cells. The functional significance of NGF expression in such a small fraction of excitatory cells in not known but it is possible that these NGF-producing neurons represent a previously unidentified subclass of excitatory neurons in the neocortex.

Our results are consistent with findings of earlier studies in other brain regions demonstrating that NGF co-localizes almost exclusively with GABAergic cells in the striatum, basal forebrain, and hippocampus ([@B38], [@B37]; [@B45]; [@B3]). Thus, NGF production by GABAergic cells may be a general property of all targets receiving basal forebrain cholinergic innervation (including the basal forebrain itself). These cholinergic neuronal populations require NGF for maintenance of their phenotype and projections ([@B53]; [@B7]; [@B27]; [@B15]). Across studies, inhibitory interneurons now emerge as the primary source of NGF trophism for basal forebrain cholinergic neurons.

Although basal forebrain cholinergic neurons innervate both excitatory and inhibitory cortical networks ([@B61]), the source of trophic support is overwhelmingly from the inhibitory population, which is known to play a critical role in mediating plasticity in cortical circuits ([@B24]; [@B60]; [@B16]). Cholinergic signaling appears to contribute to the differential activation of various inhibitory subpopulations, thereby modulating excitatory-inhibitory balance ([@B59]; [@B18]). NGF may thereby serve as a feedback signal between highly plastic inhibitory networks and the cholinergic inputs that activate them. Indeed, NGF augments plasticity and behavioral learning through cholinergic-dependent mechanisms ([@B49], [@B50]; [@B20]; [@B10]). Activity-dependent release of NGF ([@B4]; [@B39]), paired with the ability of NGF to increase cholinergic activity ([@B53]; [@B27]; [@B1]), suggests that NGF may promote reorganization of active circuits via enhanced cholinergic function.

Future studies will attempt to identify which subclasses of inhibitory neurons express NGF and how this expression precisely influences cortical circuitry. To this end, we took preliminary steps to determine whether NGF co-localized with two common markers of inhibitory neurons, parvalbumin (primarily associated with basket and chandelier cells), and calbindin (associated with numerous inhibitory cell types; [@B43]; [@B42]). Our results demonstrate that NGF was primarily detected in parvalbumin-immunoreactive cells, although many cells labeled by parvalbumin did not co-express NGF. Importantly, NGF-IR cells also colocalized with calbindin-labeled cells, suggesting that more than one subclass of inhibitory neuron produces NGF.

In summary, within the rat neocortex NGF is primarily expressed by inhibitory neurons, a property that appears to be conserved from phylogenetically older brain areas and which may generalize to the brain as a whole. Our results suggest cortical inhibitory interneurons play a vital role in the maintenance of cholinergic projection neurons of the basal forebrain. GABAergic interneurons thus may promote cortical reorganization via regulated NGF signaling.
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